Non-Hodgkin lymphoma

Non-Hodgkin lymphoma (NHL) comprises a heterogenous group of lymphoid tissue tumours, distinguished from Hodgkin’s lymphoma by their absence of Reed-Sternberg cells on ...


Read more on Non-Hodgkin lymphoma

 

Latest news articles

Added 16 days ago Drug news

NICE now approves Kymriah for treatment of diffuse large B-cell lymphoma on NHS.- Novartis

The National Institute for Health and Care Excellence (NICE) has changed its opinion and approved T-cell (CAR T-cell) therapy Kymriah...

Added 20 days ago Drug news

FDA approves Imbruvica + Gazyva combination to treat untreated chronic lymphocytic leukemia/small lymphocytic lymphoma . Abbvie + Janssen Biotech

AbbVie BV announced that the FDA approved the use of Imbruvica (ibrutinib) in combination with obinutuzumab (Gazyva) for adult patients...

Added 25 days ago Drug news

Grifols to market fostamatinib disodium hexahydrate in all potential indications in Europe and Turkey. Rigel Pharma

Rigel Pharmaceuticals, Inc. announced that it has entered into an exclusive license and supply agreement with Spain-based Grifols, S.A to...

Search all news articles for Non-Hodgkin lymphoma
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars in Oncology Knowledge Centre

Biosimilars in Oncology Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

Load more

Guidelines

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Mantle cell lymphoma is a relatively uncommon subtype of lymphoid malignancy and is more often found in males than in females. These updated ESMO guidelines provide treatment recommendations...

Added 4 years ago

Guidelines on the investigation and management of follicular lymphoma

The objective of this guideline is to provide healthcare professionals with clear guidance on the management of patients with follicular lymphoma.

Added 7 years ago

ESMO Consensus Conference on Malignant Lymphoma: General Perspectives and Recommendations for Prognostic Tools in Mature B-cell Lymphomas and Chronic Lymphocytic Leukaemia

In order to complement the already available European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with malignant lymphomas, ESMO organised a consensus conference...

Added 2 years ago

Search all guidelines for Non-Hodgkin lymphoma
 

Journal articles

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.

Background: Single-agent ibrutinib has shown substantial activity in patients with relapsed Waldenström's macroglobulinemia, a rare form of B-cell lymphoma. We evaluated the effect of adding ibrutinib to rituximab...

Added 7 months ago

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.

We compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma.

Added 1 year ago

Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.

Mantle cell lymphoma (MCL) is a lymphoproliferative disorder comprising about 6-10% of all B cell lymphoma cases. Ibrutinib is an inhibitor of Bruton tyrosine kinase (BTK), a key component of early B-cell receptor (BCR) signalling pathways.

Added 1 year ago

Search all journal articles for Non-Hodgkin lymphoma
 

Clinical trials

A Randomized Double-blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma...

Added 1 year ago

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

The primary objective of the the trial is to establish one of three study arms...

Added 2 years ago

Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial

The primary objective of the the trial is to establish one of three study arms, as future standard based on the comparison of the investigator...

Added 1 year ago

Search all clinical trials for Non-Hodgkin lymphoma
 
Fiona Holland

Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more

What to say and do when someone has cancer

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.

CME

Night sweats - red flag symptoms

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
0
Registration required
1
Subscription fee
0
Search all CME for Non-Hodgkin lymphoma